Loading...
•
Jun 29, 2024
Haemonetics Q1 2025 Earnings Report
Haemonetics' first quarter performance showcased the strength and breadth of its products, impacting attractive high-growth markets.
Key Takeaways
Haemonetics reported an 8% increase in revenue to $336 million for the first quarter of fiscal year 2025. The company reaffirmed its fiscal year 2025 guidance for revenue, adjusted operating margin, adjusted earnings per diluted share, and free cash flow.
First quarter fiscal 2025 revenue increased by 8.0% to $336.2 million compared to the same period last year.
Earnings per diluted share were reported at $0.74, while adjusted earnings per diluted share reached $1.02.
The company experienced cash outflow from operating activities of $27.4 million and a free cash outflow of $16.9 million.
Haemonetics reaffirmed its fiscal 2025 GAAP total revenue and organic revenue growth guidance.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
The Company reaffirmed its previous fiscal 2025 GAAP total revenue and organic revenue growth guidance.
Positive Outlook
- Plasma revenue decline between 3-6%.
- Blood Center revenue decline between 5-8%.
- Hospital revenue growth between 27-32%.
- Total company revenue growth between 5-8%.
- Organic growth between 0-3%.
Challenges Ahead
- Currency impact of 0% to -1%.
- Acquisitions to contribute 5-6%.
- Adjusted operating margin between 23-24%.
- Adjusted earnings per diluted share between $4.45 - $4.75.
- Free cash flow between $130M - $180M.
Revenue & Expenses
Visualization of income flow from segment revenue to net income